Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aflibercept Biomarkers in Asian DME Patients
NCT03197480Phase 4Unknown
- Sponsor
- Singapore National Eye Centre
- Start
- Apr 2019
- Primary completion
- Dec 2020
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aflibercept in diabetic macular edema (DME), sponsored by Singapore National Eye Centre. Primary endpoint: Central Retinal Thickness at 12 months. Status: unknown.
02
Drugs
aflibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT03197480.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03197480.